title: Bridging the gap between a TB drug and its target.
abstract: A promising new TB drug cocrystallized with its mycobacterial target provides a platform for structure-based design that will improve TB drug development (Neres et al.).
authors.affiliation: Department of Microbiology and Immunology, Otago School of Medical Sciences, University of Otago, Post Office Box 56, Dunedin 9054, New Zealand. gregory.cook@otago.ac.nz
authors.forename: Gregory M
authors.initials: GM
authors.lastname: Cook
authors.forename: Adam
authors.initials: A
authors.lastname: Heikal
mesh_terms: D000995:Antitubercular Agents / Q000737:chemistry* / Q000494:pharmacology*; D050296:Microbial Viability / Q000187:drug effects*; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D013843:Thiazines / Q000737:chemistry* / Q000494:pharmacology*
chemical_list: D000995:Antitubercular Agents; D013843:Thiazines